Aug 25, 2020 8:09am EDT Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH
Aug 20, 2020 7:00am EDT Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET
Jul 27, 2020 7:00am EDT Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Jul 20, 2020 7:00am EDT Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Jul 15, 2020 7:00am EDT Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
Jun 30, 2020 7:00am EDT Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Jun 09, 2020 7:00am EDT Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.
Jun 08, 2020 7:25am EDT Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020
